A green stability-indicating RP-HPLC-UV method using factorial design for determination of ribavirin, sofosbuvir and ledipasvir: Application to average content, acid degradation kinetics and in vitro drug interactions study
Sign Up to like & getrecommendations! Published in 2020 at "Microchemical Journal"
DOI: 10.1016/j.microc.2020.105251
Abstract: Abstract A novel optimization approach based on full factorial design was generated for developing a green, rapid and simple RP- HPLC-UV gradient method for simultaneous assay of recent antiviral drugs of hepatitis C (sofosbuvir and… read more here.
Keywords: sofosbuvir ledipasvir; ribavirin sofosbuvir; method;
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Sign Up to like & getrecommendations! Published in 2017 at "Value in health regional issues"
DOI: 10.1016/j.vhri.2016.10.002
Abstract: BACKGROUND The advent of highly efficacious, well-tolerated, all-oral direct-acting antiviral regimens has revolutionized the standard of care for patients chronically infected with hepatitis C virus. As efficacy and safety rates converge, prescribers and payers need… read more here.
Keywords: sofosbuvir ledipasvir; budget impact; treatment; daclatasvir asunaprevir ... See more keywords
Non-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir / Ledipasvir Treatment: A case report.
Sign Up to like & getrecommendations! Published in 2023 at "Current drug safety"
DOI: 10.2174/1574886318666230406083939
Abstract: BACKGROUND The development of direct-acting antivirals directed against the Hepatitis C Virus has dramatically modified the therapeutic approach to chronic hepatic viral disease. Larger use of such drugs has also led to increasing reports about… read more here.
Keywords: vasculitis; sofosbuvir ledipasvir; leucocytoclasic vasculitis; non anca ... See more keywords
Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report
Sign Up to like & getrecommendations! Published in 2022 at "Infectious Disease Reports"
DOI: 10.3390/idr14040061
Abstract: The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a… read more here.
Keywords: efficacy safety; treatment; sofosbuvir ledipasvir; aged years ... See more keywords